Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)
Condition: Psoriatic Arthritis Interventions: Drug: Guselkumab; Drug: Golimumab Sponsors: University of Pennsylvania; Janssen Scientific Affairs, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials